一把“双刃剑”——基质干细胞治疗心肌梗死的新观点

A double-edged sword——Mesenchymal stem cell therapy for myocardial infarction

干细胞疗法是治疗心肌梗死的新希望。国内外大量的研究表明,基质干细胞因其独特的生物学特性可作为理想的治疗细胞,在动物实验中显示出了很好的疗效。然而,本文作者领导的研究组在国际上首先证明基质干细胞存在不利于心肌梗死恢复的负性调控作用,并且在分子、细胞和在体动物水平阐明其机制。此研究提示基质干细胞疗法治疗心肌梗死可能是一把"双刃剑"。

Stem cell therapy is a new hope for the treatment of myocardial infarction. A large number of domestic and international studies have shown that mesenchymal stem cell is an ideal candidate for treatment of myocardial infarction because of its unique biological characteristics, and has shown good therapeutic efficacy in animal experiments. However, the research group led by professor Yi Dinghua first proves mesenchymal stem cells have negative regulatory effect that is not conducive to the recovery of myocardial infarction, and clarifies the underlying mechanism in molecular, cellular and in vivo animal levels. These findings indicate mesenchymal stem cell therapy for myocardial infarction might be a double-edged sword.